Dr. Duriseti is interested in the interplay between ablative radiotherapy and the immune system. Specifically, he is interested in the discovery and development of targeted agents that mimic the anti-tumor response , and other protein-based agents, for therapeutic and diagnostic purposes in oncology.
Schiff J, Spraker M, Duriseti S, et al. Case report of tumor lysis syndrome after treatment with Lattice SBRT. Advances in Radiation Oncology, 2021.
Duriseti S, et al. Lattice stereotactic body radiotherapy for large tumors. Advances in Radiation Oncology, 2021.
Kavanaugh J, Duriseti S, et al. LITE SABR M1: Planning design and dosimetric endpoints for a Phase I trial of Lattice SBRT. Radiotherapy and Oncology, 2021.
Duriseti S, et al. LITE SABR M1: a phase I trial of Lattice SBRT for large tumors. Radiotherapy and Oncology, 2021.
Orukari I, Perkins S, Zhao T, Huang J, Caruthers DF, Duriseti S. Brainstem toxicity in pediatric patients treated with protons using a single-vault synchrocyclotron system. International Journal of Particle Therapy, 2022.